Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

623

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer
PD-L1 Negative

Interventions

DRUG: Sacituzumab Govitecan-hziy
DRUG: Paclitaxel
DRUG: nab-Paclitaxel
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

Gilead Sciences